David Hong
Affiliations: | Stanford University, Palo Alto, CA |
Area:
Psychiatry and Behavioral SciencesGoogle:
"David Hong"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dy GK, Govindan R, Velcheti V, et al. (2023) Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202524 |
| Alhalabi O, Groisberg R, Zinner R, et al. (2023) Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. Npj Precision Oncology. 7: 37 |
| Raghav KP, Stephen B, Karp DD, et al. (2022) Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal For Immunotherapy of Cancer. 10 |
| Yao S, Meric-Bernstam F, Hong D, et al. (2022) Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Scientific Reports. 12: 8701 |
| Thein KZ, Piha-Paul SA, Tsimberidou A, et al. (2021) Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Experimental Hematology & Oncology. 10: 59 |
| Kato S, Adashek JJ, Subbiah V, et al. (2021) A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Investigational New Drugs |
| Tsimberidou AM, Hong DS, Fu S, et al. (2021) Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. Npj Precision Oncology. 5: 21 |
| Hong DS, Strickler JH, Fakih M, et al. (2021) Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101). Journal of Clinical Oncology. 39: TPS2669-TPS2669 |
| Vo HH, Fu S, Hong DS, et al. (2021) Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. Journal of Clinical Oncology. 39: 3140-3140 |
| Alhalabi O, Hahn AW, Msaouel P, et al. (2020) Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Molecular Cancer Research : McR |